News

News

BioImaginix Receives NSF Funding to Advance AI-Based Brain Imaging Technology

Morgantown,  WV, April 10, 2025—BioImaginix, a West Virginia-based Biotech company, today announced it has received a grant from the National Science Foundation (NSF) to support its research and development of an AI-based brain imaging algorithm. The funding will enable the company to expand further research and product development in imaging technology. The broader impact of this Small Business Innovation Research (SBIR) project is to develop a low-cost diagnostic tool for brain imaging using an AI/machine learning (ML)-based algorithm. The goal of the proposal is to develop a technology that can distinguish mild cognitive impairment (MCI) patients and Alzheimer's disease (AD) cases using MRI scans. Diagnosing AD at the MCI stage and therapeutic intervention at this stage are the keys to developing disease-modifying therapeutics, lifestyle changes, and future planning for patients, caregivers, and stakeholders. Clinical diagnosis of AD is miserably low (~60% specificity and sensitivity). Such an image analysis platform will ensure a sophisticated tool for geriatric primary care and neurologists to detect a predementia patient with a certain chance of being converted to AD shortly. In the broader commercial potential, the user-friendly brain imaging data analysis platform will be transferred to the clinic to assist in the early diagnosis of AD, particularly the MCI stage and prognosis, using MRI images. Most AD therapeutic trials have miserable outcomes. One of the key reasons for failure is designing the disease-modifying clinical trials at the advanced stage of the disease when irreversible brain damage and neuronal losses have already occurred.

“The technology BioImaginix is developing will revolutionize the brain imaging diagnostics,” says Tapan Khan, PhD, Founder & CEO of BioImaginix."  The company is in the process of implementing the AI algorithm to help diagnose brain changes due to Autism, Schizophrenia, Drug addiction, and Long-term depression.

BioImaginix is a West Virginia-based company that specializes in applying cutting-edge AI and statistical techniques, including large language models (LLMs) and multimodal LLMs, to real-world problems. Our strength lies in rapidly prototyping and deploying state-of-the-art intelligent systems that can handle complex, heterogeneous healthcare data, text, audio, images, or any combination thereof.

The National Science Foundation (NSF) is an independent agency of the United States government responsible for promoting scientific research and education.

Contact:

Manabika Khan

Business Operations Manager and Co-Founder

manabikakundukhan12@gmail.com

304-398-5130

BioImaginix Got Selected as Member of ARPA-H Investor Catalyst Hub Spoke Network 

Date: 15 October, 2024

Biolmaginix published an Al/ML algorithm that diagnoses Alzheimer’s disease (AD) and Mild Cognitive Impairment (MCI). The algorithm achieved classification accuracies of AD versus MCI 81.41% and autopsy-confirmed AD vs. MCI 92.75%. Using only MRI scans, the primary goal of the study is to test the ability to classify AD from CN and MCI cases. By overcoming the data leakage problem, the autopsy-confirmed ML classification model is tested in two independent cohorts. External validation by an independent cohort improved the quality and novelty of the classification algorithm. The proposed method of MRI analysis will be cost-effective. The algorithm is validated with NIH “Gold Standard” autopsy-confirmed AD cases and can differentiate early AD from late MCI patients. The algorithm can be used for the correct diagnosis of neurological diseases such as Schizophrenia, Autism, and Multiple Sclerosis, etc.